CytoMed Therapeutics (GDTC) Invested Capital (2021 - 2025)

CytoMed Therapeutics has reported Invested Capital for 5 years, with the latest figure at $315963.5 in Q4 2025.

• Quarterly Invested Capital fell 2.7% year-over-year to $315963.5 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $650393.8 (down 3.22% YoY) and the FY2025 annual result came in at $313433.1, down 3.07% from the prior year.
• Invested Capital slipped to $315963.5 in Q4 2025 per GDTC's latest filing, from $324737.4 in the prior quarter.
• Over five years, Invested Capital peaked at $327162.4 in Q4 2023 and troughed at $9693.0 in Q2 2024.
• A 5-year average of $174458.7 and a median of $216168.6 in 2022 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2024: Invested Capital surged 1168.22% in 2022, then fell 7.16% in 2024.
• Over 5 years, Invested Capital stood at $17045.0 in 2021, then jumped by 1168.22% to $216168.6 in 2022, then soared by 51.35% to $327162.4 in 2023, then dropped by 0.74% to $324737.4 in 2024, then slipped by 2.7% to $315963.5 in 2025.
• According to Business Quant data, Invested Capital over the past three periods registered $315963.5, $324737.4, and $9693.0 for Q4 2025, Q4 2024, and Q2 2024 respectively.